.svg){kind=small} | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | Bothell, Washington, United States (1989) |
| Founder | George Rathmann Robert Nowinski Christopher Henney |
| Defunct | 29 January 2007 |
| Fate | Acquired, Dissolved |
| Successor | CMC ICOS Biologics, Inc. |
| Headquarters | , United States |
Key people | George Rathmann (Founder, CEO, Chairman) Paul Clark (CEO, Chairman) |
| Products | Cialis |
| Revenue | US$ 71,410,000 (2005)[1] |
| US$ −74,242,000 (2005)[1] | |
| US$ −74,842,000 (2005)[1] | |
| Total assets | US$ 241,767,000 (2005)[1] |
| Total equity | US$ −59,270,000 (2005)[1] |
Number of employees | 700 (2006) |
Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007. It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and chief executive officer (CEO) and co-founder of Amgen.[2] Icos focused on the development of drugs to treat inflammatory disorders. During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials. Icos also manufactured antibodies for other biotechnology companies.
Icos is best known for the development of tadalafil (Cialis), a drug used to treat erectile dysfunction. This drug was discovered by GlaxoSmithKline, developed by Icos, and manufactured and marketed in partnership with Eli Lilly. Boosted by a unique advertising campaign led by the Grey Worldwide Agency, sales from Cialis allowed Icos to become profitable in 2006. Cialis was the only drug developed by the company to be approved.[3] LeukArrest, a drug to treat shock, and Pafase, developed for sepsis, were both tested in phase III clinical trials, but testing was discontinued after unpromising results during the trials. Eli Lilly acquired Icos in January 2007, and most of Icos's workers were laid off soon after.[4] CMC Biologics, a Danish contract manufacturer, bought the remnants of Icos and retained the remaining employees.[4]
- ^ a b c d e "ICOS Corporation Annual Report". Securities and Exchange Commission. March 8, 2006. Archived from the original on August 27, 2017. Retrieved January 17, 2009.
- ^ Cite error: The named reference
ervinwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Icos salewas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Tartakoffwas invoked but never defined (see the help page).
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search